Trans-arterial Radioembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 17
- 主要终点
- Response to radioembolization
研究概览
简要总结
In patients with hgepatocellular carcinoma (HCC) and portal vein tumoral thrombosis (PVTT), Sorafenib represents the treatment of choice but more recently, trans-arterial radioembolization (TARE) with yttrium-90 has been also proposed. A considerable percentage of such patients are not only able to achieve stability of the disease, but also to obtain a complete radiological response (CR). The possibility of achieving a CR might allow these patients to be listed for liver transplantation (LT), in order to cure not only the cancer but also the underlying cirrhosis that generated it.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of HCC;
- •age ≥ 18 years;
- •performance status according to Eastern Cooperative Oncology Group 0-1;
- •preserved liver function (Child-Pugh score ≤B7);
- •PVTT limited to the first order portal branch.
排除标准
- •any contraindication to TARE treatment;
- •macrovascular invasion extended to the main portal trunk and/or to the contralateral portal branch;
- •presence of extra-hepatic disease
结局指标
主要结局
Response to radioembolization
时间窗: 6 months
The primary endpoint of this study was to assess the effect of radioembolization in HCC patients with PVTT
次要结局
- Overall survival(5 years)
- Progression-free survival(5 years)
研究者
Rita Golfieri
Chief of Radiology Unit
IRCCS Azienda Ospedaliero-Universitaria di Bologna